Tesamorelin
Tesamorelin is a synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH). It was developed to stimulate the pituitary gland to increase growth hormone (GH) secretion, which in turn elevates levels of Insulin-like Growth Factor 1 (IGF-1). Tesamorelin is FDA-approved for a very specific indication (reducing visceral adipose tissue in HIV-associated lipodystrophy), but its broader use in anti-aging, body composition, and regenerative research remains experimental.
How It Is Used in Research Settings
- Investigated for its role in reducing visceral and abdominal fat through stimulation of endogenous GH.
- Studied in metabolic research models for improvements in insulin sensitivity and lipid metabolism.
- Explored for potential effects on muscle preservation and lean mass maintenance in aging models.
- Used in preclinical settings for cognition and neuroprotective outcomes linked to IGF-1 signaling.
Proposed Uses (Research Areas)
- Body composition research — reduction of visceral fat, increase in lean mass.
- Metabolic studies — insulin resistance, lipid metabolism, cardiovascular risk markers.
- Aging models — potential support for GH/IGF-1 decline with age.
- Neuroprotection — early data suggests possible cognitive benefits via IGF-1 pathways.
How It Is Dosed in Research Settings
- Injectable: 1–2 mg subcutaneous injection once daily, usually administered at night to mimic natural GH secretion patterns.
- Cycle length: Many research protocols run for 12–16 weeks; some extend longer in metabolic studies.
- Handling: Reconstituted with bacteriostatic water and stored refrigerated, protected from light, per research SOPs.
Important Considerations
- Regulatory status: FDA-approved only for HIV-associated lipodystrophy. All other uses remain experimental.
- Evidence base: Supported by clinical trials in its approved indication; broader use (anti-aging, fat loss, cognitive health) is still under research.
- Safety: Reported side effects include injection site reactions, joint pain, fluid retention, and insulin resistance. Long-term safety outside approved use is not established.
Disclaimer
This material is provided for educational purposes only and summarizes published research on Tesamorelin.
It is not medical advice. Except for its narrow FDA-approved use, Tesamorelin is considered experimental and should not be viewed as a general therapy for medical use.
This peptide is for research use only.